{"filing":{"accession_number":"0001802768-26-000014","cik":"0001802768","ticker":"RPRX","company_name":"Royalty Pharma plc","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"rprx-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276826000014/rprx-20260805.htm"},"events":[{"id":25258,"run_id":22919,"accession_number":"0001802768-26-000014","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Royalty Pharma issued a press release on August 5, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Portfolio Receipts of $773 million (6% growth), Royalty Receipts of $768 million (14% growth), and raising full-year 2026 guidance for Portfolio Receipts to $3,400–$3,500 million. This is a standard quarterly earnings release with detailed financial metrics, portfolio performance, and forward guidance, furnished as Exhibit 99.1 per Item 2.02.","company_name":"Royalty Pharma plc","ticker":"RPRX","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":26036,"accession_number":"0001802768-26-000014","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Royalty Pharma issued a press release on August 5, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Portfolio Receipts of $773 million (6% growth), Royalty Receipts of $768 million (14% growth), and raising full-year 2026 guidance for Portfolio Receipts to $3,400–$3,500 million. This is a standard quarterly earnings release with detailed financial metrics, portfolio performance, and forward guidance, furnished as Exhibit 99.1 per Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:23:32.285771+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26036,"accession_number":"0001802768-26-000014","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Royalty Pharma issued a press release on August 5, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Portfolio Receipts of $773 million (6% growth), Royalty Receipts of $768 million (14% growth), and raising full-year 2026 guidance for Portfolio Receipts to $3,400–$3,500 million. This is a standard quarterly earnings release with detailed financial metrics, portfolio performance, and forward guidance, furnished as Exhibit 99.1 per Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:23:32.285771+00:00","company_name":"Royalty Pharma plc","ticker":"RPRX","filing_date":"2026-08-05"}]}